

Drug consumption and costs of the glaucoma therapy in the Republic of Serbia

Aleksandra D. Ćoškov1, Dijana R. Savanović2, Nemanja B. Todorović1, Mladena N. Lalić-Popović1,3, Nataša Z. Tomić4, Boris Ž. Milijašević5

1 Department of Pharmacy, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia
2 Clinic of Cardiology, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
3 Centre for Medical and Pharmaceutical Investigations and Quality Control (CEMPhIC), Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia
4 Emergency Centre, Clinical Centre of Vojvodina, Novi Sad, Serbia

5 Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia

1. Introduction

Glaucoma is the leading cause of blindness worldwide and it is estimated that more than 70 million people suffer from this disease. The main goal of glaucoma therapy is to preserve sufficient visual function and the patient's quality of life. Drug therapy is the main type of glaucoma treatment because it is effective, safe, practical, cheap and most of them are prescribed in the form of drops for local use.

2. Methods

The research is based on a retrospective analysis of data for the period from 2015 to 2020, which were collected from the official websites of the Agency for Medicines and Medical Devices of Serbia and the Institute for Public Health of Serbia "Dr. Milan Jovanović Batut" for examining the consumption and costs of medicines in the Republic of Serbia.

3. Results

The annual consumption of all antiglaucoma drugs in the Republic of Serbia in the period from 2015-2020 is presented on the Table 1. As for drugs that are not in fixed combinations, the highest consumption was of drug from the group of prostaglandin analogues (latanoprost), followed by drug from the group of beta blockers (timolol). In the other hand, betaxolol consumption was lowest, as well as brimonidine (10 ml bottle) and pilocarpine.

The most frequently used fixed combination of drugs was timolol-dorzolamide, while the least used were timolol-brimonidine and brimonidine-brinzolamide.

Based on a review of the costs of antiglaucoma drug therapy per patient on a monthly and annual basis in the Republic of Serbia over a five-year period (Table 2), it can be seen that latanoprost is the drug with the lowest price for monthly and annual therapy. In addition, timolol also had a lower price compared to other drugs in glaucoma therapy. The price of the monthly therapy of the fixed combination of timolol-dorzolamide as well as the combination of timolol-latanoprost was lower than the price of the monthly therapy of other drug combinations (Table 2).

Table 1. Annual consumption of drugs in glaucoma therapy in the Republic of Serbia in the period 2015-2020.

ATC	Pack			Ye	ar		
INN		2015	2016	2017	2018	2019	2020
S01EA05	5m1	94 761	113881	128420	143756	172107	174308
brimonidine	10m1	14 476	13 561	12 605	14 869	3 292	9 321
S01EB01	10m1	35 976	31 155	8 988	8 107	7 455	6 385
pilocarpine							
S01EC03	5 m1	21 269	31 711	14 043	30 090	31 527	29 326
dorzolamide							
S01EC04	5 m1	48 532	66 388	63 229	9 838	77 240	69 680
brinzolamide							
S01ED01	5m1	317023	391390	312 039	105100	216280	319280
timolol	10m1	22 271	18 798	19 187	11 756	2 727	5 927
S01ED02	5m1	3 239	3 804	3 467	_	-	_
betaxolol							
S01EE01	2.5m1	401748	310339	319 404	377329	404291	409735
latanoprost							
S01EE04	2.5m1	20 713	25 088	26 105	11 410	23 650	31 340
travoprost							
S01EE03	3m1	28 468	42 465	53 753	61 568	49 411	43 640
bimatoprost							
S01EE05	30x0.3m1	11 090	13 406	19 065	37 498	57 300	65 812
tafluprost							
S01ED51	3m1	27 669	36 420	40 403	47 269	40 019	36 329
timolol, bimatoprost							
S01ED51	2.5m1	41 411	51 511	38 898	48 457	51 841	53 708
timolol, latanoprost							
S01ED51	2.5m1	894	752	1 966	6 750	6 750	10 530
timolol, travoprost							
S01ED51	5m1	343393	305230	112 507	336880	409419	382005
timolol, dorzolamide							
S01ED51	5m1	2 395	5 826	31 306	7 940	52 945	59 540
timolol, brinzolamide							
S01ED51	5m1	-	1 304	3 937	2 876	1 813	1 459
timolol, brimonidine							
S01EC54	5m1	-	_	_	-	870	8 160
brimonidine, brinzolamide							

Table 2. Costs of antiglaucoma therapy per patient on a monthly and annual basis in the Republic of Serbia in the period 2015-2020.

INN,	BBB	MDC	Price Year								
Pack	DDD	(ml)	(RSD)	2015 639.80	2016 639.80	2017 639.80	2018 568.50	2019 563.57	2020 563.57		
Brimonidine 5ml	0.2	6	1DDD	25.59	25.59	25.59	22.74	22.54	22.54		
Brime 5ml			MT AT	767.76 9 213.12	767.76 9 213.12	767.76 9 213.12	682.2 8 186.40	676.28 8 115.36	676.28 8 115.36		
			P	566.40	566.40	566.40	562.00	557.20	557.20		
Brimonidine 10ml	0.2	6	1DDD MT	566.40	566.40	566.40	562.00	557.20	557.20		
Brin 10m			AT	6 796.80	6 796.80	6 796.80	4 744.00	6 686.40	6 686.40		
pine			P 1DDD	155.7 6.23	155.7 6.23	155.7 6.23	154.5 6.18	153.17 6.13	153.17 6.13		
Pilocarpine 12ml	0.4	12	MT	186.84	186.84	186.84	185.4	183.8	183.8		
P			AT	2 242.08 588.90;	2 242.08 588.90;	2 242.08 588.90;	2 224.80 584.30;	2 205.60 579.30;	2 205.60 579.30;		
			P	464.40 35.33;	464.40 35.33;	464.40 35.33;	431.40 35.05;	427.70 34.75;	427.70 34.75;		
mide	0.3	9	1DDD	27.86 1059.81;	27.86 1059.81;	27.86 1059.81;	25.88 1051.53;	25.66 1042.53;	25.66 1042.53;		
Dorzolamide 5ml			MT	835.75 13917.72	835.75 13917.72	835.75 13917.72	776.36 12618.36;	769.71 12510.36;	769.71 12510.36;		
			AT	10029.00	10029.00	10029.00	9316.32	9236.52	9236.52		
Brinzolamide 5ml			P 1DDD	848.20 33.93	848.20 33.93	848.20 33.93	748.20 29.95	647.90 25.92	647.90 25.92		
inzola i	0.2	6	MT	1 017.84	1 017.84	1 017.84 12	898.56	777.48	777.48		
Br 5m			AT	12214.08	12214.08	214.08	10782.72	9 329.76	9 329.76		
loi	0.2	6	P 1DDD	252.00 10.08	252.00 10.08	242.00 10.08	9.60	9.52	237.97 9.52		
Timolol 5ml	0.2		MT AT	302.40 3 628.80	302.40 3 628.80	302.40 3 628.80	288.12 3 547.44	285.56 3 426.72	285.56 3 426.72		
			P	353.40	353.40	353.40	350.60	347.60	347.60		
Timolol I0ml	0.2	6	1DDD MT	353.40	353.40	353.40	350.60	347.60	347.60		
Tim 10n			AT	4 240.80	4 240.80	4 240.80	4 207.20	4 171.20	4 171.20		
			P 1DDD	270.40	270.40	270.40	-	-	-		
Betaxolol 5ml	0.2	6	MT	10.82 324.48	10.82 324.48	10.82 324.48	-	-			
Beta 5ml			AT	3 893.76	3 893.76	3 893.76	-	-	_		
			P	554.60;	554.60;	554.60;	530.10;	525.50;	525.50;		
			1000	638.40 22.18;	638.40 22.18;	638.40 22.18;	609.40 21.20;	604.10 21.02;	604.10 21.02;		
tso	0.1	3	1DDD	25.54	25.54	25.54	24.38	24.16	24.16		
70p7 1			MT	665.52; 766.08	665.52; 766.08	665.52; 766.08	636.12; 731.28	630.60; 724.92	630.60; 724.92		
Latanoprost 2.5ml			AT	7986.24; 9192.96	7986.24; 9192.96	7986.24; 9192.96	7633.44; 8775.36	7567.20; 8699.04	7567.20; 8699.04		
			P	1 419.90	1 419.90	1 419.90	1 408.80	1 396.67	1 396.67		
15			1DDD	47.33	47.33	47.33	46.96	46.55			
opro	0.1	3	MT	1 419.90	1 419.90	1 419.90	1 408.80	1 396.67	1 396.67		
Bimatoprost 3ml			AT	17038.	17038.	17038.	16905.60	16760.04	16760.04		
50 m				80	80	80					
			P 1DDD	1 464.20 58.57	1 464.20 58.57	1 464.20 58.57	1 122.20 44.89	1 018.50 40.74	1 018.50		
Travoprost 3ml	0.1	3	MT	1 787.04	1 787.04	1 787.04	1 346.64	1 222.20	1 222.20		
avop i											
			AT	21084.48	21084.48	21084.48	16159.68	14666.40	14666.40		
705t m3			P	1 657.50	1 657.50	1 657.50	1 644.40	1 631.87	1 631.87		
Tafluprost 30x0.3ml	0.1	3	1DDD MT	1 657.50	1 657.50	1 657.50	1 644.40	1 631.87	1 631.87		
Ta 3			AT	19890.00	19890.00	19890.00	19732.80	19582.44	19582.44		
	0.2	6	P	531.00;	531.00;	531.00;	526.90;	522.40;	522.40;		
			1DDD	638.40	638.40	638.40	633.40	629.37 20.90;	629.37 20.90;		
			ועעעוו	25.54	25.54	25.54	25.34	25.17	25.17		
nge			MT	637.20;	637.20;	637.20;	632.28;	626.88;	626.88;		
vloi, olam				766.08	766.08	766.08	760.08	755.24	755.24		
Timolol, Dorzolamide Sml			AT	7646.40; 9192.96	7646.40; 9192.96	7646.40; 9192.96	7587.36; 9120.96	7522.56; 9062.88	7522.56; 9062.88		
	0.2	6	P	1 187.40		1 187.40		1 168.00	1 168.00		
			1DDD	47.50	47.50	47.50	47.12	46.72	46.72		
mide			MT	1 424.88	1 424.88	1 424.88	1 413.72	1 401.60	1 401.60		
Timolol, Brinzolamide Sml			A TE	17000 54	17000 55	17000 50	1606161	16010.30	16010.30		
Timo Brinz 5ml			AT	17098.56	17098.56	17098.56	16964.64	16819.20	16819.20		
	0.1	3	P	598.90;	598.90;	598.90;	575.90;	575.90;	577.27;		
					638.40	638.40	628.00	628.00	628.00		
			1DDD	23.96;	23.96;	23.04;	23.04;	23.04;	23.09;		
**			MT	718.68	25.54 718.68;	25.12 718.68;	25.12 691.08;	25.12 691.08;	25.12 692.72;		
al pross			1411	, 10.00	766.08	766.08	753.60	753.60	753.60		
Timolol, Latanoprost 3ml			AT	8 624.16	8624.16;	8624.16;	8292.96;	8292.96;	8312.64;		
64%	.n. *			g mm = 11	9192.96	9192.96	9043.20	9043.20	9043.20		
7,027	0.1	3	P 1DDD	1 581.40	1 581.40	1 581.40	1 569.10	1 555.57	1 555.57		
Timolol, Bimatoprost 3ml			MT	1 581.40	1 581.40	1 581.40	1 569.10	1 555.57	1 555.57		
Time Bim 3mi			AT	18976.80				18666.84	18666.84		
	0.1	3	P	1 695.80	1 695.80	1 695.80		1 493.10	1 493.10		
25			1DDD	67.83	67.83	67.83	67.30	59.72	59.72		
Timolol, Tranoprost Sml			AT	2034.96 24419.52	2034.96 24419.52	2034.96	2019.12	1791.72 21500.64	1791.72 21500.64		
Timo Tran 3mi					نگال. الا کا کا کا کا	2.71.22	2.007.77	22500.04	21000.07		
	0.2	6	P	-	1 175.00	1 175.00		1 155.57	1 155.57		
			1DDD	-	47.00	47.00	46.63	46.22	46.22		
dine			MT	-	1 410.00	1 410.00	1 398.96	1 386.68	1 386.68		
Timolol, Brimonidine Sml			AT	_	16920.00	16920.00	16787.52	16640.16	16640.16		
Tim Brin Sml											
	0.2	6	P	-	-	-	-	1 329.00	1 329.00		
app.			1DDD	-	-	-	-	53.16	53.16		
эніа <u>і</u> э <i>іат</i>			MT	_	-	-	-	1 594.80	1 594.80		
Brimonidine Brinzolamide Sml			AT	-	-	_	-	19137.60	19137.60		
म्यम्य				[_		
					DC- Mon						

DDD- Defined daily dose; MDC- Monthly drug consumption; P-Package; MT- Monthly treatment; AT- Annually treatment

4. Conclusion

Data showed that latanoprost had the highest consumption, followed by timolol and the timolol-dorzolamide combination. Timolol was the most affordable, and drug prices generally decreased from 2015 to 2020. The biggest consumption drop occurred for pilocarpine.